News
Henlius, Sandoz Strike $322M Biosimilar Deal
Under the new agreement, Henlius will grant Sandoz exclusive rights to register and commercialize up to 10 partnered products outside China
E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Under the new agreement, Henlius will grant Sandoz exclusive rights to register and commercialize up to 10 partnered products outside China
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
